TuHURA Biosciences, Inc. Common Stock
HURAStock
$2.22−0.87%52W
Market Cap$145.20M
P/E—
Div yield—
Beta0.01
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)195.76%
Price vs S&P 500 (4W)1.65%
VGM Score66.57
Market Capitalization$145.20M
Earnings Surprise History
Q1 26-0.13est. -0.12
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HURATuHURA Biosciences, Inc. Common Stock | — | — | B | $2.22 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
TuHURA Biosciences is an immuno-oncology company advancing a personalized cancer vaccine candidate, IFx-2.0, designed to overcome primary resistance to checkpoint inhibitor immunotherapy. The company is preparing to initiate a Phase 3 registration trial evaluating IFx-2.0 in combination with Keytruda (pembrolizumab) as a first-line treatment for advanced or metastatic Merkel Cell Carcinoma.